# Executive Function Impairments in HAND and Aging

> **NIH NIH R01** · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · 2024 · $573,415

## Abstract

Project Summary:
With the great success of combination antiretroviral therapy (cART), older adults (>50 years of age) now
account for 30–50% of HIV-1 seropositive individuals in high-resource countries; a prevalence that is expected
to reach approximately 73% by 2030. Critically, older HIV-1 seropositive individuals exhibit a higher frequency
of neurocognitive impairments (NCI) relative to their younger counterparts. Neurological complications of HIV
infection are the biggest challenge facing HIV researchers, but currently, there are no efficacious treatments for
HIV-1-associated neurocognitive disorders (HAND). An innovative regenerative “dendritic spine-targeted”
therapeutic approach is proposed to address the neuropathologic hallmark of HAND: synaptodendritic
neuronal injury. The hypothesis is that a regenerative “dendritic spine-targeted” approach will alter the longi-
tudinal trajectory of HAND (i.e., delay progression of NCI) by restoring synaptodendritic integrity via the
NogoA-NgR3/PirB-RhoA signaling pathway. The specific aims are: 1) To establish efficacious “dendritic
spine-targeted” therapeutics to address HIV-1-induced synaptodendritic loss and spine dysmorphol-
ogy. Factorial design experiments will establish neurorestoration at the synaptic level following treatment with
the promising isoflavandiol estrogen S-Equol (SE) as well as a specific estrogen β-receptor agonist (SERBA,
i.e., AC-186) in sex-specified brain cell cultures. Given the well-established role of the NogoA-NgR3/PirB-RhoA
signaling pathway in synaptic function and dendritic spine growth/retraction, we will employ pharmacological
and molecular approaches to investigate whether this pathway mechanistically underlies neurorestoration. 2)
To establish the in vivo efficacy of SERBAs to alter the longitudinal trajectory of HAND in the HIV-1 Tg
rat. We will promote restoration of neurocognitive function with SERBA therapy (initially SE, a metabolite
produced via the gut microbiome following ingestion of soy isoflavone daidzein). Having utilized cross-sectional
studies to optimize the treatment conditions of SE to mitigate NCI, we are poised to establish the in vivo
efficacy of SE to alter the progression to NCI using a longitudinal design; the factor of biological sex is integral
to the experimental design. 3) To establish in vivo the neural mechanism by which SERBAs exert their
therapeutic effects. Using a time-sequential longitudinal experimental design, we will examine the regenera-
tion of synaptodendritic integrity in pyramidal neurons of the medial prefrontal cortex (mPFC) and medium
spiny neurons (MSN) of the nucleus accumbens following SERBA therapy. Using in vivo pharmacological and
molecular approaches, the NogoA-NgR3/PirB-RhoA signaling pathway will be examined to establish the
underlying neural mechanism. With recently established models, methodological advances, proof-of-concept
publications, and new preliminary data, we are in a unique position to critically t...

## Key facts

- **NIH application ID:** 10838690
- **Project number:** 1R01AG082539-01A1
- **Recipient organization:** UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
- **Principal Investigator:** Rosemarie M Booze
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $573,415
- **Award type:** 1
- **Project period:** 2024-09-24 → 2029-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10838690

## Citation

> US National Institutes of Health, RePORTER application 10838690, Executive Function Impairments in HAND and Aging (1R01AG082539-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10838690. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*